Review decision date: September 2012
It has been decided not to update this guideline at this stage. For further information, please refer to the surveillance review decision.
The guideline should cross refer to a new technology appraisal (TA236).
May 2015 - This guideline will shortly be checked to see if it needs updating, please register as a stakeholder to be informed about the decision.
Next review: October 2016
This guidance updates and replaces recommendations 1.2, 1.3, 1.4 and 1.6 in NICE technology appraisal 47 (published in September 2002) and recommendations 1.1 and 1.2 from NICE tecnology appraisal 80 (published in July 2004).
It offers evidence-based advice on the care and treatment of adults with unstable angina or NSTEMI from the time of diagnosis to leaving hospital. Unstable angina is a type of recurring chest pain, and NSTEMI (which stands for non-ST-segment-elevation myocardial infarction) is a type of heart attack.
In November 2013 changes were made to recommendations 1.3.6 and 1.5.11. See changes after publication for more details.
The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The application of the recommendations in this guideline is not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.